knowledge -WSS

knowledge

author：explore 2025-09-27 16:36:19 - browse：31936

Doctor holding a clipboard. -- health coverage from STAT — Adobe

The momentum around weight loss drugs is about to get even bigger in the wake of Novo Nordisk’s announcement that its semaglutide drug Wegovy cut the risk of cardiovascular disease by 20% in its large SELECT trial.

The full results of the study, funded by Novo, will be presented at the American Heart Association meeting in November. Doctors and researchers say they expect the findings to have a big impact on how clinicians approach the treatment of both obesity and cardiovascular disease, as well as increase the likelihood that prescriptions for obesity drugs will be covered by insurance.

But experts who spoke with STAT also cautioned that the long-term safety and efficacy of Wegovy and other weight loss drugs remain unknown. The SELECT study has yet to be peer-reviewed, and not enough information is yet available to make independent assessments of the results.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： Why the world’s most expensive drug might be worth the price

WSS

Supreme Court mifepristone arguments center on docs' right to sue

Solve the antibiotic resistance crisis with preventive drugs

FDA struggles to regulate food additives, sometimes for decades

FDA warns J&J's Abiomed: We will regulate your software

Roche subsidiary Foundation Medicine opens new headquarters

Study says nonprofit hospitals fall short in charity care spending

explore

knowledge

leisure time

Hepatitis C has a cure — but many Americans still lack access to it

Senate committee scrutinizes Medicare Advantage brokers

How to save PrEP access — and even expand it

Eli Lilly expects to double planned employment in Boston center

Duchenne breakthrough therapy leaves behind pioneering families

Senate committee scrutinizes Medicare Advantage brokers

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

There's no autism epidemic. It's an autism diagnosis epidemic

The cancer drug shortage isn’t new — and neither are the solutions

Pharmacists can make shortage drugs, but at what cost?

leisure time

Why health workers in Gaza are injured or die at high rates

CEOs share strategies for surviving biotech slump

Donor acceptance rates hint at racial, gender bias in heart transplants: study

Merck drug for rare lung condition set for approval in U.S.

First Opinion Podcast: Long Covid needs a new approach

First Opinion Podcast: Long Covid needs a new approach

leisure time

hotspot

hotspot

focus